Search Results
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
August, 2024
August 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jul
Vivek Subbiah
Sep 13, 2023, 14:04 |
Insight
Vivek Subbiah: Super thrilled to share our paper - Variant of allele frequency: a decision-making tool in precision oncology?
Vivek Subbiah, Chief, Early-Phase Drug Development, Sarah Cannon Research Institute, made the following post on…
Sep 7, 2023, 19:58 |
Insight
Vivek Subbiah: Super delighted to Join Dr. Stephen V Liu to share my thoughts...
Quoting Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, on…
Sep 7, 2023, 19:57 |
Positive
Vivek Subbiah: Keep taking steps forward, even if it feels impossible to turn back.
Quoting Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, on…
Sep 5, 2023, 17:18 |
Insight
Vivek Subbiah: Give the right drug, to the right patient, at the right time in every country, to think globally and act locally.
Quoting Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, on LinkedIn:…
Aug 31, 2023, 19:03 |
Insight
Vivek Subbiah: The evidence for different approaches to colorectal cancer screening is reviewed and a framework for evaluation of screening programs going forward is proposed.
Aug 30, 2023, 17:46 |
Insight
Vivek Subbiah: Adding chemotherapy to cemiplimab at progression might provide a new second-line treatment for patients with advanced non-small-cell lung cancer.
In a post by Vivek Subbiah, the Chief Early-Phase Drug Development at Sarah Cannon Research…
Aug 28, 2023, 17:40 |
Insight
Vivek Subbiah: Lurbinectedin was approved for Small cell Lung in USA and now is also approved in Canada, Australia, Singapore, the United Arab Emirates, Qatar, South Korea, Ecuador, Mexico, Israel and Switzerland.
Aug 27, 2023, 18:58 |
Insight
Vivek Subbiah: The 3rd KRAS G12C kid on the block.
According to Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute:…
Aug 25, 2023, 16:32 |
Insight
Vivek Subbiah: Huge win for patients with RET+ thyroid cancers.
Quoting Vivek Subbiah, the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute,…
Aug 20, 2023, 17:41 |
Insight
Vivek Subbiah: Pan-KRAS inhibitors have broad therapeutic implications and merit clinical investigation in patients with KRAS-driven cancers.
According to Vivek Subbiah, Chief, Early-Phase Drug Development, Sarah Cannon Research Institute on LinkedIn: "Pan-KRAS…
20
21
22
23
24
All:
284
Posts:
211 - 220
Matti Aapro is running for the UICC Board of Directors
CityU-AFCR Symposium on Precision Medicine and Digital Medicine
New management team at St. Anna Children's Hospital
Key Inspirational Moments with WHO Director at the Olympic Games
Remembering Susan Wojcicki, Honoring a Legacy of Leadership and Technological Innovation
Facebook
RSS Feed
Twitter
Linkedin
Youtube